On May 13, the U.S. Food and Drug Administration (FDA) approved Merck's hepatitis C drug boceprevir (trade name: Victrelis). Boceprevir is a protease inhibitor that binds to hepatitis C virus and prevents its replication. The applicable population is: Hepatitis C patients with partial liver function, Hepatitis C patients who have not used drug therapy, and Hepatitis C patients who are not treated with other drugs. Boceprevir is approved for use in combination with pegylated interferon alpha and ribavirin. The product was also approved by the European Medicines Agency (EMA). (Details click: MINENET - Member Area - "FDA approved boceprevir treatment of chronic hepatitis C")
On May 17th, Merck announced that it had reached a non-exclusive strategic agreement with Roche of Switzerland through its subsidiaries. It plans to cooperate in advanced and emerging regions to improve the treatment, diagnosis and cognitive methods of chronic hepatitis C virus. In addition, R&D personnel will further collaborate to explore new combinations of drug combinations from drugs that are already on the market or in the R&D phase of the two companies to accelerate the discovery of new and more effective Hepatitis C treatments. (Click for details: MINENET - Member Area - "Moshisha Roche establishes a strategic agreement against chronic hepatitis C")
On May 18, Abbott announced that the FDA has approved the development of its real-time PCR assay for hepatitis C viral load.
On May 23rd, Bristol-Myers Squibb announced the results of phase IIb EMERGE clinical trials of the new pegylated interferon lambda. The data show that: Compared with the current standard of pegylated interferon-alpha combined with ribavirin treatment, the use of pegylated interferon-lambda combined with ribavirin in the treatment of patients with chronic hepatitis C treatment can obtain higher rapidity Virological response rate, and safety and tolerability performed well. The pegylated interferon λ is the first interrogating type III interferon that regulates antiviral activity through its receptors. Compared with pegylated interferon α, the distribution of interferon λ receptors is more limited in hematopoietic cells. There is basically no distribution. This receptor distribution facilitates more targeted delivery of interferon in therapy. Bristol-Myers Squibb also announced the results of another small molecule drug BMS-790052.
In addition, a forecast report by Thomson Reuters shows that it is expected that by the year 2015 there will be two "heavy bombs" for the treatment of hepatitis C. In addition to Merck East's boceprevir, the other is Vertex/Johnson's telaprevir, which is expected to exceed $3 billion in sales.
Ginseng has been known as the "king of herbs", "nourishing yin, nourishing health, strengthening the root" of the best products since ancient times. It contains a variety of saponins and polysaccharides. The extract can be slowly absorbed by the skin without adverse stimulation. It can expand skin capillaries, promote skin blood circulation, increase skin nutrition, regulate skin water and oil balance, prevent skin dehydration, sclerosis, wrinkling, and suppress black by ginseng active substances. It can make skin white and smooth, enhance skin elasticity and regenerate cells. It is the best product of skin care and beauty. Dip ginseng into 50% glycerin directly, rub face with glycerin 10 days later, or fry ginseng into concentrated juice, pour a little into the wash water every day, rub face with ginseng glycerin or ginseng water, can make skin quite moist.
Functions and Indications: Dabu Yuanqi, Fumai Gutuo, Bupi Yifei, Shengjin Yangxue, Anshen Yizhi. It is used for deficiency of body, cold pulse of limbs, deficiency of spleen and food, asthma and cough of lung, thirst of body and wound, internal heat to quench thirst, deficiency of Qi and blood, chronic disease, palpitation and insomnia, impotence and palace cold.
Ginseng Extract,Ginseng Tea,Ginseng Root,Panax Ginseng
Lixian Spring Pharmaceutical Co., Ltd. , https://www.lxctyy.com